Rho’s Federal Systems Division has been selected by the U.S. Department of Health and Human Services (HHS) to be part of a network of five CROs to design and conduct clinical studies for the development of medical countermeasures, including drugs, vaccines and diagnostic tests that help protect public health against bioterrorism, pandemic influenza, and other health emergencies.
The Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR), will manage the new clinical studies network, and Rho will support targeted clinical studies relevant to BARDA's goals to quickly and effectively respond to deliberate, natural and emerging threats by providing a range of clinical study services that can be used by BARDA and its development partners.
Clinical studies will include trials evaluating chemical, biological, radiological, nuclear (CBRN), pandemic influenza and/or emerging infectious disease medical countermeasures. Also, clinical trial response readiness projects will address preparedness and response activities in advance of a public health emergency and may require the development and implementation of a detailed plan for the initiation of clinical studies within a certain timeframe.
“We are honored to have Rho’s Federal Systems Division selected by HHS to be a part of this clinical studies network,” said Russ Helms, Ph.D., chief executive officer at Rho. “This appointment reflects our team’s expertise and leadership in this field of research.”